Is NNMX or JNJ a better dividend investment in 2026?

NNMX currently yields 1000000.00% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: NNMX offers higher current income.

What is the dividend yield difference between NNMX and JNJ?

NNMX has a forward dividend yield of 1000000.00% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 999996.64 percentage points.

Home › Compare › NNMX vs JNJ

NNMX vs JNJ: Dividend Comparison 2026

NNMX yields 1000000.00% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NNMX wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NNMX

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full NNMX calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — NNMX vs JNJ

📍 NNMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NNMX	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NNMX + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NNMX pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNMX

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, NNMX beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNMX + JNJ for your $10,000?

NNMX: 50%JNJ: 50%

100% JNJ50/50100% NNMX

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NNMX

No analyst data

Altman Z

-202.4

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNMX buys

JNJ buys

No recent congressional trades found for NNMX or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNNMXJNJ

Forward yield	1000000.00% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$4.7683925249533696e+36M	$20.0K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$827.78
Total dividends collected	$4.7683311610149396e+36M	$5.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: NNMX vs JNJ ($10,000, DRIP)

Year	NNMX Portfolio	NNMX Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$10,676	$355.77	+$100.00M → NNMX
2	$934,786,450,701	$934,679,439,252.34	$11,407	$389.39	+$934786.44M → NNMX
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$12,198	$426.53	+$8165787108.57M → NNMX
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$13,056	$467.62	+$66665884190957.63M → NNMX
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$13,987	$513.12	+$508662171058048128.00M → NNMX
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$14,998	$563.56	+$3.62723524842849e+21M → NNMX
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$16,098	$619.52	+$2.417368115915061e+25M → NNMX
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$17,295	$681.69	+$1.5056740286145463e+29M → NNMX
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$18,599	$750.82	+$8.764771002818475e+32M → NNMX
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$20,022	$827.78	+$4.7683925249533696e+36M → NNMX

NNMX vs JNJ: Complete Analysis 2026

NNMX — Stock

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.

Full NNMX Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this NNMX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNMX vs SCHD NNMX vs JEPI NNMX vs O NNMX vs KO NNMX vs MAIN NNMX vs ABBV NNMX vs MRK NNMX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.